塞来昔布对良性口咽手术后阿片类药物使用及疼痛控制的影响
本研究评估扁桃体腺样体切除术(T&A)及改良悬雍垂腭咽成形术(UPPP)后使用塞来昔布对疼痛评分和阿片类药物消耗的影响。术后第1、5、10天疼痛评分无显著差异(p=0.5、p=0.2、p=0.6)。结论:术后加用塞来昔布可显著减少平均阿片类药物消耗量,且疼痛控制相似。
要点
- 术后使用塞来昔布可显著降低T&A或UPPP后的阿片类药物消耗量。
- 塞来昔布组与非塞来昔布组在术后第1、5、10天的疼痛评分无显著差异。
- 研究提示术后塞来昔布可在不牺牲疼痛控制的情况下减少阿片类药物使用。
核心结论
- 术后加用塞来昔布可显著减少T&A或UPPP后平均阿片类药物消耗量,且患者报告的疼痛评分相似。
研究设计与样本
- 前瞻性队列研究,纳入2024年5月至10月接受T&A或UPPP伴扁桃体切除术的患者,根据是否处方塞来昔布分组,非塞来昔布组为历史对照组(2020年12月至2023年1月)。
主要发现
- 塞来昔布组(N=38)平均阿片类药物消耗量为66.2 mL(SD=62.1),非塞来昔布组(N=42)为118.4 mL(SD=91.6)(p=0.021)。
- 术后第1、5、10天疼痛评分在两组间无显著差异(p=0.5、p=0.2、p=0.6)。
关键数值与推荐
- 所有患者均接受多模式镇痛方案,队列基于是否处方塞来昔布划分。
- 使用Wilcoxon秩和检验和卡方检验,通过R Studio进行统计分析。
临床怎么用
- 对于接受T&A或UPPP的患者,术后可考虑加用塞来昔布以减少阿片类药物消耗,同时维持相似的疼痛控制。
局限性
- 非塞来昔布组为历史对照,可能存在时间偏倚。
- 样本量较小,需更大样本量的研究进一步确定术后塞来昔布使用的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To establish how celecoxib use after tonsillectomy and adenoidectomy (T&A) and modified uvulopalatopharyngoplasty (UPPP) affect pain scores and opioid consumption. METHODS: Patients undergoing T&A or UPPP with tonsillectomy (May-October 2024) completed surveys on postoperative days (POD) 0, 1, 5, and 10 to assess pain scores and opioid use. All patients received a multimodal pain regimen, and cohorts were based on the prescription of celecoxib. The noncelecoxib cohort was a historical control group obtained via study data from Butkus et al. (December 2020-January 2023). Wilcoxon rank-sum and chi-squared tests were performed using R Studio. RESULTS: Eighty patients were included (mean 33.0 years [SD = 12]), 66% female; 34% male; 55% Caucasian. The celecoxib cohort (N = 38) consumed an average of 66.2 mL (SD = 62.1) of opioids, and the non-celecoxib cohort (N = 42) received an average of 118.4 mL (SD = 91.6) (p = 0.021). There were no significant differences in pain scores reported on POD 1, 5, or 10 (p = 0.5, p = 0.2, p = 0.6, respectively). CONCLUSION: The addition of postoperative celecoxib resulted in a significant decrease in mean opioid consumption. Our data also demonstrate that postoperative pain was controlled similarly based on patient reported pain scores, regardless of celecoxib consumption. Further investigation is warranted with larger sample sizes to determine the efficacy of postoperative celecoxib use.
引用
- Platukus A, Kaki P, Kaffenes A, et al. Postoperative Effects of Celecoxib on Opioid Use and Pain Control After Benign Oropharyngeal Surgery. Laryngoscope. 2026. PMID: 41906254. doi:10.1002/lary.70530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。